Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...
Medical Device Network on MSN
Edwards Lifesciences served $10M penalty over JC Medical acquisition violations
The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
JP Morgan upgraded Edwards Lifesciences (EW) to overweight from neutral highlighting accelerating growth in its transcatheter aortic valve replacement (TAVR) division and strength in its transcatheter ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve ...
Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results